Get the Stockscreener App
36.85
5.02%
1.76
Exelixis Inc stock is traded at $36.85, with a volume of 3.44M.
It is up +5.02% in the last 24 hours and up +1.15% over the past month.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
See More
Previous Close:
$35.09
Open:
$36.105
24h Volume:
3.44M
Relative Volume:
1.54
Market Cap:
$10.31B
Revenue:
$2.08B
Net Income/Loss:
$466.92M
P/E Ratio:
23.62
EPS:
1.56
Net Cash Flow:
$404.94M
1W Performance:
+5.29%
1M Performance:
+1.15%
6M Performance:
+39.95%
1Y Performance:
+77.85%
1-Day Range:
$35.88
$37.05
1-Week Range:
$34.01
$37.05
52-Week Range:
$20.14
$37.59
Exelixis Inc Stock (EXEL) Company Profile
Name
Exelixis Inc
Sector
Industry
Phone
(650) 837-7000
Address
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
Compare EXEL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
36.85 | 10.31B | 2.08B | 466.92M | 404.94M | 1.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-27-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-24-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-17-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-16-24 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-19-24 | Initiated | UBS | Neutral |
| Apr-11-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-19-23 | Initiated | BTIG Research | Buy |
| Dec-15-23 | Initiated | Citigroup | Buy |
| Sep-26-23 | Initiated | H.C. Wainwright | Buy |
| Aug-22-23 | Reiterated | Oppenheimer | Outperform |
| Aug-08-23 | Initiated | SVB Securities | Market Perform |
| Jul-11-23 | Resumed | Morgan Stanley | Equal-Weight |
| May-10-23 | Resumed | Piper Sandler | Overweight |
| Mar-09-23 | Initiated | Wells Fargo | Overweight |
| Jan-26-23 | Initiated | Credit Suisse | Outperform |
| Oct-18-22 | Initiated | JMP Securities | Mkt Outperform |
| Jun-24-22 | Initiated | BMO Capital Markets | Outperform |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Nov-03-21 | Resumed | Jefferies | Buy |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Aug-06-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-15-21 | Initiated | H.C. Wainwright | Buy |
| May-18-21 | Resumed | Goldman | Sell |
| Mar-31-21 | Initiated | Credit Suisse | Outperform |
| Mar-12-21 | Initiated | Wolfe Research | Outperform |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-13-20 | Initiated | SunTrust | Buy |
| Nov-13-19 | Initiated | BofA/Merrill | Buy |
| Mar-18-19 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Sep-17-18 | Initiated | Goldman | Neutral |
| Sep-10-18 | Initiated | Morgan Stanley | Underweight |
| May-11-18 | Reiterated | Needham | Buy |
| Oct-17-17 | Reiterated | Needham | Buy |
| Oct-17-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-16-17 | Reiterated | SunTrust | Buy |
| Sep-22-17 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Sep-12-17 | Reiterated | Needham | Buy |
| Jul-14-17 | Initiated | SunTrust | Buy |
| Mar-31-17 | Initiated | Needham | Buy |
| Mar-16-17 | Initiated | Oppenheimer | Perform |
| Feb-28-17 | Downgrade | Stifel | Buy → Hold |
| Nov-03-16 | Initiated | Deutsche Bank | Buy |
| Oct-10-16 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Sep-15-16 | Reiterated | Stifel | Buy |
View All
Exelixis Inc Stock (EXEL) Latest News
Exelixis (EXEL) Stock Jumps Amid New Share Buyback Announcement - GuruFocus.com
Why Exelixis Stock Trounced the Market on Thursday - Nasdaq
Why Is Cancer-Focused Exelixis Stock Trading Higher On Friday? - AOL
Why Exelixis Shares Are Skyrocketing: A Story of Triumph and Strategy - Jomfruland.net
Exelixis' (NASDAQ:EXEL) Earnings May Just Be The Starting Point - Yahoo Finance
Exelixis Inc.: Pipeline Expansion & Innovation to Build A Robust Portfolio! - Smartkarma
Exelixis Board Authorizes Additional Share Buyback Program of Up To $500 Million; Shares Advance After Hours - Marketscreener.com
Exelixis Approves Additional $500 Mln Stock Buyback Program - Nasdaq
Exelixis Announces a Newly Authorized $500 Million Stock Repurchase Program - The Bakersfield Californian
Is Exelixis (EXEL) a Solid Growth Stock? 3 Reasons to Think "Yes" - Nasdaq
Exelixis director Sue Gail Eckhardt sells shares worth $405,111 By Investing.com - Investing.com South Africa
Exelixis director George Poste sells $551,462 in stock By Investing.com - Investing.com Australia
Exelixis director Mary Beckerle sells $425,878 in stock By Investing.com - Investing.com Australia
Exelixis director Sue Gail Eckhardt sells shares worth $405,111 - Investing.com India
Exelixis director Freire Maria C sells $1.54 million in stock - Investing.com India
Exelixis director Mary Beckerle sells $425,878 in stock - Investing.com India
Exelixis director Freire Maria C sells $1.54 million in stock By Investing.com - Investing.com Nigeria
Exelixis Executives Sell Shares in February Transactions - TradingView
Exelixis looks to next-gen cancer drug as Cabometyx underwhelms again - PharmaLive
Exelixis's SWOT analysis: cabo patent win boosts stock outlook By Investing.com - Investing.com Nigeria
Exelixis Gains 6.7% Post Q4 Earnings: Is This the Right Time to Buy? - MSN
Exelixis's SWOT analysis: cabo patent win boosts stock outlook - Investing.com
Exelixis falls after ASCO releases colorectal cancer data - MSN
International Markets and Exelixis (EXEL): A Deep Dive for Investors - Nasdaq
Five-year results see Exelixis’ RCC therapy extending overall survival - Yahoo Finance
Exelixis stock rating cut by Oppenheimer, price target to $33 from $41 - MSN
JMP Securities maintains Exelixis stock with $41 target - MSN
Exelixis Full Year 2024 Earnings: EPS Beats Expectations - Yahoo Finance
Exelixis (NASDAQ:EXEL) Releases Quarterly Earnings Results, Misses Estimates By $0.03 EPS - MarketBeat
Exelixis (NASDAQ:EXEL) Stock Rating Lowered by StockNews.com - MarketBeat
State of Alaska Department of Revenue Decreases Position in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Exelixis, Inc. (NASDAQ:EXEL) Q4 2024 Earnings Call Transcript - MSN
Piper Sandler Increases Exelixis (NASDAQ:EXEL) Price Target to $38.00 - MarketBeat
Sapient Capital LLC Invests $256,000 in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Exelixis (NASDAQ:EXEL) Receives "Buy" Rating from HC Wainwright - MarketBeat
Exelixis (EXEL) Q4 Earnings and Revenues Top Estimates - MSN
Exelixis Announces Final Five-Year Follow-up Results from CheckMate -9ER Trial Evaluating CABOMETYX - Business Wire
Exelixis (NASDAQ:EXEL) Given New $29.00 Price Target at Barclays - MarketBeat
Q3 Earnings Forecast for Exelixis Issued By Leerink Partnrs - MarketBeat
Citigroup Issues Positive Forecast for Exelixis (NASDAQ:EXEL) Stock Price - MarketBeat
Polaris Capital Management LLC Sells 16,900 Shares of Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Empowered Funds LLC Takes $7.46 Million Position in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
EXELExelixis Inc Latest Stock News & Market Updates - StockTitan
Stifel Nicolaus Forecasts Strong Price Appreciation for Exelixis (NASDAQ:EXEL) Stock - MarketBeat
Stifel raises Exelixis stock price target to $36, maintains hold - MSN
Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy? - Nasdaq
Exelixis, Inc. (NASDAQ:EXEL) Holdings Lifted by Allspring Global Investments Holdings LLC - MarketBeat
Exelixis to Participate in the Citi 2025 Virtual Oncology Leadership Summit - BioSpace
FY2025 EPS Estimates for Exelixis Reduced by Leerink Partnrs - MarketBeat
Exelixis stock holds firm with $41 target from JMP Securities - MSN
Exelixis targets $5B Zanza sales by 2033 with multiple pivotal trials in progress - MSN
Exelixis Inc Stock (EXEL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Exelixis Inc Stock (EXEL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Beckerle Mary C | Director |
Feb 14 '25 |
Sale |
34.88 |
12,210 |
425,878 |
30,406 |
| POSTE GEORGE | Director |
Feb 14 '25 |
Option Exercise |
20.50 |
15,874 |
325,417 |
184,894 |
| POSTE GEORGE | Director |
Feb 14 '25 |
Sale |
34.74 |
15,874 |
551,463 |
169,020 |
| Freire Maria C | Director |
Feb 14 '25 |
Option Exercise |
21.52 |
44,114 |
949,521 |
135,121 |
| Freire Maria C | Director |
Feb 14 '25 |
Sale |
34.94 |
44,114 |
1,541,343 |
91,007 |
| Eckhardt Sue Gail | Director |
Feb 14 '25 |
Option Exercise |
23.24 |
7,712 |
179,227 |
41,974 |
| Eckhardt Sue Gail | Director |
Feb 14 '25 |
Sale |
35.02 |
11,568 |
405,111 |
30,406 |
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):